Lululemon Athletica inc. (NASDAQ:LULU), founder Dennis “Chip” Wilson has lost that Zen feeling since being ousted as the head of the yoga retailer–and might be taking steps to retake control. Lululemon Athletica inc. (NASDAQ:LULU), net profit margin is 18.30% and weekly performance is 7.84%. On last trading day company shares ended up $41.25. Analysts mean target price for the company is $42.77. Lululemon Athletica inc. (NASDAQ:LULU), distance from 50-day simple moving average (SMA50) is -8.44%.
On June 09, 2014, China Ming Yang Wind Power Group Ltd (NYSE:MY) recently got approval for development and operation of 300MW offshore wind power project. China Ming Yang Wind Power Group Ltd (NYSE:MY), advanced 4.00% in last trading session and ended the day on $3.64. MY, Gross Margin is 9.20% and its return on assets is -4.50%. China Ming Yang Wind Power Group Ltd (NYSE:MY), quarterly performance is 10.64%.
Genocea Biosciences Inc (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. Genocea Biosciences Inc (NASDAQ:GNCA), shares moved down 2.95% in last trading session and was closed at $22.03, while trading in range of $21.01 – 23.99. Genocea Biosciences Inc (NASDAQ:GNCA), year to date (YTD) performance is 100.27%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO), announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. INO-3112 is a combination of Inovio’s lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12). VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia (pre-cancer). Inovio Pharmaceuticals Inc (NYSEMKT:INO), ended the last trading day at $9.36. Company weekly volatility is calculated as 3.75% and price to cash ratio as 4.82. Inovio Pharmaceuticals Inc (NYSEMKT:INO),showed a positive weekly performance of 5.52%.
Micron Technology, Inc. (NASDAQ:MU), will report its third-quarter (3Q) earnings for fiscal 2014 (FY14) earnings after markets close. The average of analysts’ revenue estimates is $3.89 billion, an increase of 67% year-over-year (YoY). The EPS projection is 69 cents. Micron Technology, Inc. (NASDAQ:MU), net profit margin is 21.30% and weekly performance is -2.04%. On last trading day company shares ended up $31.26. Analysts mean target price for the company is $35.33. Micron Technology, Inc. (NASDAQ:MU), distance from 50-day simple moving average (SMA50) is 14.64%.